However, two separate trials have been reported using a DNA vaccine encoding a prostate tumor antigen, prostatic acid phosphatase (PAP, pTVG-HP) in patients with early recurrent prostate cancer or more advanced castration-resistant, metastatic prostate cancer (mCRPC) [144,176]. This evidence concerns the gene ACP3 and Familial prostate cancer.